Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dmt + harmine
- Development stage
- Phase 1
- Lead developer
- Reconnect Labs
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Oral, Intranasal, Buccal
01
Overview
DMT + harmine is a combination of N,N-dimethyltryptamine (DMT), a potent psychedelic tryptamine, and harmine, a reversible inhibitor of monoamine oxidase A (MAO-A). This combination is inspired by the traditional Amazonian brew ayahuasca. When administered together, harmine inhibits MAO-A in the gut and liver, preventing the rapid breakdown of orally or nasally administered DMT. This allows DMT to become bioavailable and active for an extended period when taken by routes other than smoking or injection. The result is a phenomenologically rich psychedelic experience characterized by vivid visual hallucinations, mystical experiences, psychological insights, emotional breakthroughs, and lasting positive effects on well-being[1][2][3]. Harmine alone has minimal psychoactive effects at tolerated doses but enables the oral activity of DMT through MAO-A inhibition[4][6][7]. The combination can be delivered via various routes (e.g., nasal spray for DMT with buccal/oral tablet for harmine) and produces effects similar to those reported in ayahuasca ceremonies[5].
- Other names
- DMT/harmineDMT + harmine combinationayahuasca-inspired DMT/HAR formulation
02
Targets
HTR2A (Serotonin receptor 5-HT2A)DYRK1A (Dual-specificity tyrosine-phosphorylation-regulated kinase 1A)MAOA (Monoamine oxidase A)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on dmt + harmine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dmt + harmine.